Tag: paroxysmal AF
J&J MedTech presents new Omny-IRE and VARIPURE study data at HRS...
Johnson & Johnson (J&J) MedTech has announced positive initial three-month results from the Omny-IRE study evaluating the investigational Omnypulse platform in patients with paroxysmal...
Farapulse PFA system demonstrates superior efficacy to cryoablation catheter in paroxysmal...
New findings from the SINGLE SHOT CHAMPION trial, presented at the ongoing European Heart Rhythm Association (EHRA) congress (30 March–1 April 2025, Vienna, Austria)...
Boston Scientific launches next generation of cardiac mapping for Farapulse PFA...
Boston Scientific Corporation has announced that it has received US Food and Drug Administration (FDA) approval of the navigation-enabled Farawave Nav ablation catheter for...
AF pattern at first diagnosis does not appear to influence post-ablation...
A patient’s pattern of atrial fibrillation (AF) at their initial diagnosis does not influence their rate of AF recurrence, nor their AF burden, following...
Boston Scientific receives Japanese regulatory approval for Farapulse PFA system
Boston Scientific has announced receipt of Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the Farapulse pulsed field ablation (PFA) system. The...
AF Symposium 2022: Lower pulmonary vein to left atrium volume ratio...
Pulmonary vein-left atrial (PV/LA) volume ratio is a significantly better predictor power for atrial fibrillation (AF) recurrence than LA dimension in patients with normal...